Mergers and Acquisitions

Anju Completes Merger with OmniComm Systems to Form eClinical Entity

September 18, 2019

The merger creates a combined organization with a leading position in the eClinical market.

Lundbeck to Acquire Alder BioPharmaceuticals in Deal Worth Up to $1.95 Billion

September 16, 2019

The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.

PPF Acquires Stake in Autolus Therapeutics, Expands Cell Therapy Pipeline

September 16, 2019

The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.

JWP Acquires Euvipharm for Further Growth in Pharmerging Market

September 05, 2019

JW Pharmaceutical Corp will acquire the rights to 100% of the shares of Euvipharm along with a state-of-the-art pharmaceutical plant located in Vietnam.

Roche, Spark Therapeutics Acquisition Delayed Under Regulatory Review

September 04, 2019

Roche has extended its offering period for the purchase of Spark to provide US and UK regulatory authorities with additional time to complete their review of the acquisition.

Vertex to Acquire Semma Therapeutics in $950-Million Deal

September 04, 2019

Vertex will use the acquisition to develop cell-based treatments for type 1 diabetes.

Ajinomoto Bio-Pharma to Acquire Joint Venture Granules OmniChem in India

August 29, 2019

The transaction will reach completion during the fourth quarter of 2019.

LBB Specialties Enters into Strategic Partnership for Excipient Product Distribution

August 29, 2019

LBB Specialties and Meggle Excipients & Technology will work to distribute excipient products to companies in the American pharmaceutical and nutraceutical industries.

Bristol-Myers Squibb, Celgene to Divest Otezla to Amgen for $13.4 Billion

August 26, 2019

The transaction is part of Bristol-Myers Squibb’s proposed acquisition of Celgene.

Bayer to Sell Animal Health Biz to Elanco for $7.6 Billion

August 21, 2019

The divestiture is in line with Bayer’s strategy to focus on its life sciences business.